Orchid Pharma DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.89×	0.95×	1.04×	1.00×	0.84×
	2.69×	−1.08×	1.16×	1.19×	1.92×
	0.4%	−0.8%	9.0%	9.5%	4.3%
	0.62×	0.62×	0.57×	0.59×	0.57×
	1.44×	1.44×	1.33×	1.33×	1.78×
	0.9%	0.7%	8.2%	8.8%	7.1%
	0.7%	0.7%	8.2%	9.9%	6.9%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ORCHPHARMA₹893.40

Orchid Pharma Limited

· Pharma & Health

₹ CrorePeersFDC GUJTHEM IOLCP MOREPENLAB RPGLIFE GUFICBIO INNOVACAP UNICHEMLABMcap ₹5,350 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.84	1.00	1.04	0.95	0.89
Interest Burden (Pretax/EBIT) ×	1.92	1.19	1.16	-1.08	2.69
EBIT Margin %	4.33	9.45	8.96	-0.78	0.42
Asset Turnover ×	0.57	0.59	0.57	0.62	0.62
Financial Leverage (Assets/Equity) ×	1.78	1.33	1.33	1.44	1.44
ROE (5-step product, year-end total equity) %	7.05	8.82	8.21	0.72	0.89
ROE (owners' profit / average owners' equity) %	6.93	9.92	8.18	0.70	0.70

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.